SILENT-SEEDS
14.12.2022 18:13:43 CET | Business Wire | Press release
Seed bank Silent Seeds and famous breeder Mario Guzman, founder of Sherbinskis, are proud to announce their partnership in a range of five unique US exotic varieties.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005114/en/
(Photo: Silent Seeds)
Following an initial highly successful collaboration with the rapper Booba and the creation of his own seed strain (B-45), the Silent Seeds teams are proud to be embarking on a significant new strategic partnership with Mario Guzman, one of the best breeders of his generation.
Creator of the brand Sherbinskis, his work is recognized and appreciated worldwide. He is particularly well known for developing two of the most iconic strains in the cannabis world: Gelato and the Gelato lineage of Bacio, Acaiberry, Mochi and Gello, and the famous Sunset Sherbert.
The collaboration between Silent Seeds and Sherbinskis will offer a range of five unique US exotic varieties, of which 3 are feminized (Polar Gelato, Pink Sunset, and Acai Jelly) and 2 are autoflowering (Polar Gelato Auto and Pink Sunset Auto). They are available at www.silent-seeds.com.
Strongly inspired by the US spirit and Californian vibes, this collection signals the initial stage in marrying together knowledge that is recognized as the best in the world and the will to achieve genetic excellence.
"We are very excited about our partnership with Mario Guzman, confirming the return of Silent Seeds as a leader in the field. This is due to the work by all the teams, boasting experience of more than 20 years, and our strategic action plan since we took over Dinafem's historic genetics bank." - Alexandre-Henri Lacarré, CEO of Silent Seeds
The collaboration also signals the transatlantic ambitions of Silent Seeds, with the launch of a growth project to be completed by the end of 2023.
The teams from Silent Seeds and Sherbinskis will be delighted to meet you at the next edition of Spannabis, March 10 to March 12, 2023, Europe's leading international Cannabis Fair. Stand 129, Hall 1. Over two days, at the conference and in meetings, Mario Guzman will be sharing his vision and experience with all attendees.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005114/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shilpa Medicare and Gate2Brain Sign Strategic Equity Partnership to Advance First-in-Class Brain Cancer Therapy8.6.2026 12:00:00 CEST | Press release
Shilpa Biocare Pvt Ltd, a Subsidiary of Shilpa Medicare Limited (BSE/NSE: SHILPAMED) has entered a strategic equity partnership with Gate2Brain, S.L., a biotechnology company focused on CNS therapeutics. Shilpa becomes a strategic shareholder and CMC, manufacturing, and regulatory partner for G2B-002 — Gate2Brain's lead program targeting deadly pediatric brain cancers, DIPG and pGBM, both with Orphan Drug Designation from the US FDA and EMA. G2B-002 uses Gate2Brain's proprietary MiniAp4 peptide shuttle to deliver SN-38 across the blood-brain barrier, demonstrating up to 100-fold greater brain drug transport preclinically. First-in-human trials are anticipated by FY28. G2B-002 targets high-growth oncology markets — the glioblastoma market projected at USD 6.48B by 2035 (CAGR: 7.97%), pediatric brain tumors at USD 2.47B by 2031 (CAGR: 6.9%), and DIPG at USD 1.2B by 2035 (CAGR: 7.1%). Gate2Brain's MiniAp4 platform further extends potential across rare pediatric cancers and broader CNS cat
Haleon Invests in India to Deliver Better Everyday Health to Rural Communities8.6.2026 11:11:00 CEST | Press release
£175m for first Haleon manufacturing site in Madhya Pradesh, central IndiaFast-growing India key to Haleon reaching one billion more consumers by 2030India’s consumer health market to reach over £23bn by 20301Accelerated rural distribution to access 3 million outletsAffordable Sensodyne packs and investment to double ‘last-mile’ reach in rural areas Haleon, a consumer company that is solely focused on better everyday health, today announces plans to expand its business in India, one of its fastest-growing markets and key to Haleon delivering its strategy and ambitions to reach one billion more consumers by 2030. Haleon will invest approximately £175 million2 in building a new oral health manufacturing site in Madhya Pradesh, central India and accelerate distribution efforts in rural India to meet rising demand. The new site will also support supply for wider Asia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608753094/e
Diabetology’s Breakthrough Clinical Data From Oraglutide™ Oral GLP-18.6.2026 10:56:00 CEST | Press release
Oraglutide™ Once Weekly, Low Dose, Low side-effect, Oral GLP-1 Glucose and Insulin Response Over 6 days: Clinical Data Posted at World ADA Diabetes & Obesity Conference Diabetology Limited (Jersey) poster presentation (https://diabetology.co.uk/ada-poster) 1724-P at the ADA 86th Scientific Session, New Orleans, reporting first human data from Oraglutide™ — small capsule intestinally-released oral semaglutide, formulated using the proprietary Axcess™ delivery technology. KEY HIGHLIGHTS 6-day glucose control: A single 4 mg oral dose of Oraglutide™ produced a sustained fall in glucose. Measuring 14% at Day 6 (p=.046), the longest duration presented from a single oral GLP-1 dose in a human IVGTT study. 28% increase in insulin secretion: Relative to placebo, insulin percent AUC increased by 12% day 0, (p=0.02) & 28% Day 1 (p = 0.025). Novel intestinal depot effect: Blood levels of semaglutide were higher on Day 1 than dosing on Day 0, consistent with lipid associated depot effect in the int
Reply at VivaTech 2026: Making AI, Agents and Robotics Happen Across the Enterprise8.6.2026 10:00:00 CEST | Press release
Reply[EXM, STAR: REY] is taking part in VivaTech 2026, Europe's largest innovation and technology event, held from June 17 to 20 at Paris Expo Porte de Versailles. At the event, Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260608667672/en/ At VivaTech 2026 Reply will showcase its latest innovations around AI for software engineering, AI-powered experiences, data and AI, and industrial AI. Industries are being reshaped by AI, autonomous agents, robotics and new digital experiences. From strategy to execution, Reply helps companies move beyond experimentation and innovative ideas into concrete business value. Visitors can meet Reply in Hall 7.1, booth 1G12, and explore how, through real use cases, scalable solutions and live demonstrations, the group makes innovation happen. This year, Reply'
Cardiolife Partners with Bhutan Ministry of Health to Strengthen Nationwide Cardiac Care8.6.2026 10:00:00 CEST | Press release
Cardiolife is proud to partner with the Ministry of Health of Bhutan to roll out its advanced AI-powered ECG diagnostics system nationwide. The collaboration will provide access to early ECG diagnosis and prevention, marking a major step forward in the country’s effort to strengthen heart health and preventive care. Bhutan has a population of just over 700,000 people and heart failure and other cardiac conditionsare among the leading causes of death. Following constructive meetings in Thimphu, His Excellency, the Health Minister, officially endorsed the national rollout of Cardiolife’s solution and expressed appreciation for Cardiolife’s commitment to advancing cardiac care through the provision of free software and ECG equipment in Bhutan. “We are grateful to the Cardiolife team for their commitment to improving heart health in Bhutan. With cardiovascular diseases on the rise, this collaboration marks an important milestone in our journey to strengthen early detection and prevention a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
